Abstract:There are 91 known capsular serotypes of Streptococcus pneumoniae. The nasopharyngeal carriage prevalence of particular serotypes is relatively stable worldwide, but the host and bacterial factors that maintain these patterns are poorly understood. Given the possibility of serotype replacement following vaccination against seven clinically important serotypes, it is increasingly important to understand these factors. We hypothesized that the biochemical structure of the capsular polysaccharides could influence the degree of encapsulation of different serotypes, their susceptibility to killing by neutrophils, and ultimately their success during nasopharyngeal carriage. We sought to measure biological differences among capsular serotypes that may account for epidemiological patterns. Using an in vitro assay with both isogenic capsule-switch variants and clinical carriage isolates, we found an association between increased carriage prevalence and resistance to non-opsonic neutrophil-mediated killing, and serotypes that were resistant to neutrophil-mediated killing tended to be more heavily encapsulated, as determined by FITC-dextran exclusion. Next, we identified a link between polysaccharide structure and carriage prevalence. Significantly, non-vaccine serotypes that have become common in vaccinated populations tend to be those with fewer carbons per repeat unit and low energy expended per repeat unit, suggesting a novel biological principle to explain patterns of serotype replacement. More prevalent serotypes are more heavily encapsulated and more resistant to neutrophil-mediated killing, and these phenotypes are associated with the structure of the capsular polysaccharide, suggesting a direct relationship between polysaccharide biochemistry and the success of a serotype during nasopharyngeal carriage and potentially providing a method for predicting serotype replacement.

Bacterial polysaccharides as vaccines--immunity and chemical characterization

Current Understanding on Biosynthesis of Microbial Polysaccharides

Extended Polysaccharide Analysis within the Liposomal Encapsulation of Polysaccharides System

Immunology of bacterial polysaccharide antigens

Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins

Carrier Proteins Facilitate the Generation of Antipolysaccharide Immunity via Multiple Mechanisms

Streptococcus pneumoniae polysaccharides conjugated to the outer membrane protein A from Klebsiella pneumoniae elicit protective antibodies

State of pneumococcal vaccine immunity

Polysaccharide and conjugate vaccines to Streptococcus pneumoniae generate distinct humoral responses

Chemical Synthesis of Truncated Capsular Oligosaccharide of Serotypes 6C and 6D of Streptococcus pneumoniae with Their Immunological Studies

Studies on Vaccine Control and Immunogenicity of Polysaccharides of Streptococcus pneumoniae

Polysaccharide conjugate vaccine: A kind of vaccine with great development potential

Pneumococcal Capsular Polysaccharide Structure Predicts Serotype Prevalence

Polysaccharides As Vaccine Adjuvants

Attachment of capsular polysaccharide to the cell wall in Streptococcus pneumoniae

Recent Developments in Synthetic Oligosaccharide-Based Bacterial Vaccines

Bacterial Polysaccharides with Zwitterionic Charge Motifs: Toll-Like Receptor 2 Agonists,T Cell Antigens, or Both?

Bacterium-like Particles from Corynebacterium pseudodiphtheriticum as Mucosal Adjuvant for the Development of Pneumococcal Vaccines

Preparation and preclinical evaluation of two novel Staphylococcus aureus capsular polysaccharide 5 and 8‐fusion protein (Hla‐MntC‐SACOL0723) immunoconjugates

Decoding capsule synthesis in Streptococcus pneumoniae

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models